Sandoz Group AG (SDZNY OTCGREY) stock market data APIs
$86.1997
0.48(0.6%)
as of February 12, 2026
Try our APIs with
free plan!
Sandoz Group AG Financial Data Overview
Price chart is built with
Anychart
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Prev. Close
86.1997
Open
86.684
High
86.7911
Low
85.7389
52 wk Range
34.9663-86.8
Market Cap
38 311 M
P/E Ratio
164.9616
Shares Outstanding
431 M
Revenue
10 587 M
Dividends (Yield)
0.0081
Beta
0.259
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Sandoz Group AG (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sandoz Group AG data using free add-ons & libraries
Get Sandoz Group AG Fundamental Data
Sandoz Group AG Fundamental data includes:
- Net Revenue: 10 587 M
- EBITDA: 1 023 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sandoz Group AG News
New
How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat
Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri. Continue Reading
Sandoz Canada launches first ophthalmology biosimilar
Sandoz Canada expands portfolio launching Enzeevu®, company's first ophthalmology biosimilar Enzeevu® is approved for all indications of reference medicine EYLEA® 1, including neovascular age-relat...
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
Alvotech REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for pati...
Are Investors Undervaluing Sandoz Group AG (VTX:SDZ) By 44%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sandoz Group fair value estimate is CHF110 Sandoz Group is estimated to be 44% undervalued based on current share price of CHF61.72 The US$56....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
